Brian G. Short, DVM, PhD, DACVPv

Dr. Short is a  toxicologist and toxicologic pathologist. He has contributed to over 100 regulatory submissions in the US, EU, Australia and Japan, coauthored over 40 peer review publications, and been a Diplomate of the American College of Veterinary Pathology since 1985.  With over 17 years of ocular pharmaceutical and biotechnology development experience at Allergan, Dr. Short has directed Pathology and Toxicology departments and provided guidance for interpretation of results of safety studies including pathology peer review, risk assessments, positioning adverse findings, evaluation of in-licensing candidates and review of nonclinical development plan strategies.  He has led nonclinical development teams regarding an intravitreal anti-angiogenic biologic (DARPin) for the neovascular form of age-related macular degeneration and an intravitreal implant (brimonidine) for neuroprotection in geographic atrophy.  He has contributed to global marketing approval for many ophthalmic drugs or devices (Restasis®, Lumigan®, Alphagan®, Ozurdex®, Trivaris®, and Refresh/Optive®) as well as neurologic (BOTOX®) and dermal (Aczone®, Tazorac®) drugs.

Recent Publications


Related Articles

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Regul Toxicol Pharmacol. 2014 Oct;70(1):413-29

Authors: Sewell F, Chapman K, Baldrick P, Brewster D, Br


Related Articles

Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.

Toxicol Pathol. 2013;41(8):1159-69

Authors: Perry R, Farris G, Bienvenu JG, Dean C, Foley G, Mahrt C, Short B, Society of Toxicologic Pathology


Related Articles

RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.

Am J Ophthalmol. 2010 Jul;150(1):33-39.e2

Authors: Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, Reisen G, Lockridge JA, Short B, Guerciolini R, Nguyen QD, Sirna-027 Study Investigators

Related Articles

Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.

Toxicol Pathol. 2010 Jun;38(4):522-53

Authors: Vahle JL, Finch GL, Heidel SM, Hovland DN, Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B, Todd MD

Related Articles

Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.

Toxicol Pathol. 2010 Jan;38(1):43-50

Authors: Long GG, Morton D, Peters T, Short B, Skydsgaard M